Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Tandem Diabetes Care Inc (NASDAQ: TNDM) closed the day trading at $21.15 down -1.54% from the previous closing price of $21.48. In other words, the price has decreased by -$1.54 from its previous closing price. On the day, 1.3 million shares were traded.
Ratios:
For a better understanding of TNDM, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.81 and its Current Ratio is at 2.30. In the meantime, Its Debt-to-Equity ratio is 3.18 whereas as Long-Term Debt/Eq ratio is at 2.78.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on April 10, 2025, initiated with a Neutral rating and assigned the stock a target price of $20.
On March 05, 2025, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also lowered its target price recommendation from $45 to $22.
Citigroup Downgraded its Buy to Neutral on March 04, 2025, whereas the target price for the stock was revised from $35 to $24.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 07 ’25 when Kyrillos Jean-Claude bought 10,538 shares for $18.12 per share. The transaction valued at 190,966 led to the insider holds 10,538 shares of the business.
BLICKENSTAFF KIM D sold 30,000 shares of TNDM for $941,400 on Nov 21 ’24. The Director now owns 165,190 shares after completing the transaction at $31.38 per share. On Nov 20 ’24, another insider, BLICKENSTAFF KIM D, who serves as the Director of the company, sold 10,000 shares for $30.00 each. As a result, the insider received 300,000 and left with 195,190 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.43 while its Price-to-Book (P/B) ratio in mrq is 9.07.
Stock Price History:
Over the past 52 weeks, TNDM has reached a high of $53.69, while it has fallen to a 52-week low of $15.75. The 50-Day Moving Average of the stock is 7.73%, while the 200-Day Moving Average is calculated to be -32.36%.
Shares Statistics:
A total of 66.57M shares are outstanding, with a floating share count of 65.98M. Insiders hold about 0.95% of the company’s shares, while institutions hold 111.43% stake in the company.
Earnings Estimates
The current assessment of Tandem Diabetes Care Inc (TNDM) involves the perspectives of 19.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.25, with high estimates of $0.05 and low estimates of -$0.44.
Analysts are recommending an EPS of between -$1.11 and -$2.84 for the fiscal current year, implying an average EPS of -$1.53. EPS for the following year is -$0.7, with 21.0 analysts recommending between -$0.25 and -$1.41.
Revenue Estimates
18 analysts predict $238.07M in revenue for the current quarter. It ranges from a high estimate of $243.22M to a low estimate of $234.1M. As of the current estimate, Tandem Diabetes Care Inc’s year-ago sales were $221.91MFor the next quarter, 18 analysts are estimating revenue of $250.09M. There is a high estimate of $267M for the next quarter, whereas the lowest estimate is $235M.
A total of 21 analysts have provided revenue estimates for TNDM’s current fiscal year. The highest revenue estimate was $1.03B, while the lowest revenue estimate was $995.28M, resulting in an average revenue estimate of $1B. In the same quarter a year ago, actual revenue was $940.2MBased on 21 analysts’ estimates, the company’s revenue will be $1.11B in the next fiscal year. The high estimate is $1.15B and the low estimate is $1.06B.
